RxDoctor Payments DataLook up a doctor →

Anne Marie Miles, MD

Nephrology · Miami, FLNPI 1669467429

Payments from drug & device makers

$418,990in general payments, 2019–2025

Across 506 payments — averaging $828.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$355K
  • Merck$41K
  • CSL Behring$18K
  • Calliditas Therapeutics US Inc.$2K
  • Amgen$781
  • Otsuka America Pharmaceutical, Inc.$283
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$2,10042%
  • Food & beverage$2,89857%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$418,990 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$174,133
Medicare patients
387
Services billed
1,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol116$111,853
JardianceEmpagliflozin84$67,254
KerendiaFinerenone97$62,754
RayaldeeCalcifediol14$17,750
ProsolParenteral Amino Acid 20% No.150$14,669
LokelmaSodium Zirconium Cyclosilicate13$5,923
Eplerenone15$2,056
Sevelamer Carbonate17$2,028
Calcitriol55$968
Nifedipine ErNifedipine28$651
Losartan Potassium52$571
Dutasteride16$566
Furosemide68$252
Hydralazine Hcl16$148
Tamsulosin Hcl13$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$117$117,777129 claims
Boehringer IngelheimJardiance$29$67,25484 claims
BayerKerendia$117$62,75497 claims
OPKO Pharmaceuticals, LLCRayaldee$201$17,75014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →